Autoimmune diseases, allergies and chronic inflammations affect about 2-15% of the world population, with rising prevalences, high healthcare burdens and socio-economic impacts costing hundreds of billion dollars annually (Miller FW, Curr. Opin. Immunol., 2023). 

The 2025 Nobel Prize for Medicine, awarded to Prof M. Brunkow, Prof F. Ramsdell, and Prof S. Sakaguchi for their discovery of peripheral immune tolerance by regulatory T cells, highlights the critical role of the immune tolerance mechanism that was embedded in the human immune system to protect us from autoimmune diseases, allergies, GvHD, transplant rejections, and other chronic inflammatory conditions. The manifestations of chronic inflammation in these conditions typically arise from an imbalance between autoreactive inflammatory and immune tolerance responses of the host.

Despite significant advances in treatments achieved with mAb biologics and small molecule inhibitors, between 10- 50% of patients will fail to respond or eventually developed resistance to current treatments. The current therapeutic paradigm and strategies primarily targets suppression of inflammation by blocking pro-inflammatory cytokines or intracellular signaling pathways without addressing the immune tolerance side of the equation to address the key underlying cause of diseases. These treatments also pose serious risks of infections and immuno-compromises due to a broad immunosuppression as a lifelong medication.  The current clinical challenges represent a significant unmet patient need. An ideal therapy should aim to induce or rebalance immune tolerance responses without compromising the host’s immune defense.

Anti-IgD monoclonal antibody (mAb) is a first-in-class, disease-modifying therapeutic mAb that binds to immunoglobulin D (IgD) expressed on B cells to activate the immune responses to engage our body’s inbuilt regulatory immune tolerance mechanisms and anti-inflammatory responses to address the underlying causes of human autoimmune diseases, allergies and chronic inflammations.

Distinctively different from the current treatments with immunosuppressants, anti-IgD mAb is designed to activate a particular immune response, rather than suppressing it, to engage and harness our body’s inbuilt immune tolerance mechanisms and regulatory feedback anti-inflammatory responses. Anti-IgD mAb restores the balances between the immune tolerance and pro-inflammatory states by activating regulatory T cells and regulatory B cells, inducing anergic and regulatory phenotypes in B cells, selectively depleting harmful IgD+ mature B cells, and promoting an anti-inflammatory Th2-leaning response to deliver a long last therapeutic effect with minimal compromises to the host’s protective immunity against infections (Nguyen TG, Int. Rev. Immunol., 2022). 

IMT aims to develop anti-IgD mAb as an innovative, paradigm shifting, and disease modifying mAb treatment for human chronic inflammations including autoimmune diseases, allergic conditions, graft versus host diseases (cGVHD), organ transplant rejections, chronic obstructive pulmonary diseases (COPDs), and potentially Alzheimer’s and Parkinson’s diseases. IMT also intends to design anti-IgD mAb as a platform adaptable to other potential modalities.

The preclinical proof of concept of anti-IgD mAb originated from postdoctoral research works and discoveries by IMT Chief Scientific Officer and Founder, Dr Tue (Tommie) Gia Nguyen, demonstrating the novel therapeutic efficacies, safety and modes of action (MoA) of anti-IgD mAb in clinically relevant mouse models of rheumatoid arthritis, atopic and allergic contact dermatitis.  These findings on therapeutic efficacies and MoA of anti-IgD mAb have been recently confirmed and corroborated by other independent studies in various mouse models of other autoimmune and allergic conditions. The peer-reviewed publications and corroborating evidence relevant to anti-IgD mAb technology are available on IMT Research Publications link.

IMT Business Overview

IMT Business & Product

Our business goal is to advance the humanized anti-IgD mAb to human clinical trials as a first-in-class, disease-modifying treatment for chronic human inflammation including autoimmune diseases, allergies, graft versus host diseases (GVHD), organ transplant rejection, chronic obstructive pulmonary diseases (COPDs), cardiovascular inflammations (atherosclerosis, myocarditis) and neuroinflammations (Strokes, Alzheimer’s and Parkinson’s diseases).

The key product and asset of IMT is a first-in-class humanized anti-IgD mAb therapeutic drug that is designed to activate the body’s immune system to engage its own inbuilt immune tolerance mechanisms and anti-inflammatory responses to induce long lasting disease remission.

IMT will utilize its innovation, know-how and intellectual properties (IP), scientific research insights and knowledge in human diseases and in the biology of IgD and anti-IgD mAb to design and to produce a humanized anti-IgD mAb drug that leverage on a unique combination of clinically proven therapeutic target (B cells), modes of actions (immune tolerance), and mAb biologic modality (renowned for its blockbuster market successes) that differentiate anti-IgD mAb technology from the current therapeutics in the market to address their current unmet patient needs.  This technological leverage will thereby enable anti-IgD mAb to compete and gain market shares in the targeted market segments of early-stage refractory patients with moderate to severe autoimmune diseases, allergies, and others immune-mediated conditions who fail to respond to currently available treatments.

IMT Business Case & Investment Opportunity

IMT business model and strategic pathways aim to achieve its commercialization and business goals via licensing or strategic partnerships with major pharmaceutical and biotech companies that will fund the development of our product from clinical trials to market approvals in major markets for therapeutic antibody biologics.

Autoimmune diseases, allergic reactions, and chronic inflammations affect approximately 2–15% of the global population, with increasing prevalence, substantial healthcare burdens, and profound socio impacts costing hundreds of billions of dollars annually (Miller FW, Curr. Opin. Immunol.,2023). Between 10-50% of patients fail to respond or eventually develop resistance to the currently available drug treatments. The market for therapeutic treatments of human autoimmune diseases and allergic conditions currently has a market value of >US$200 billion p.a. in sales revenues and the annual sales of the current blockbuster therapeutic antibody drugs for these conditions exceed US$115 billion p.a. with significant unmet patient needs and rising demands for a novel therapeutic approach with better efficacy and less adverse side-effects that anti-IgD mAb technology aims to address.

Based on our market and technology assessment, anti-IgD mAb has the potential of gaining market share in the unmet medical needs segment that potentially equates to >US$5b in annual sales revenue in the current market of therapeutic antibody treatments for these human conditions if it gains regulatory and market approvals. 

IMT is currently looking for funding from family office, investment funds, venture capitals, and accredited professional investors to advance the clinical development of our humanized anti-IgD mAb to human clinical trial.  IMT is also looking for partnerships/collaborations with existing pharmaceutical and biotechnology companies. 

IMT aims to raise US$16 million in capital to fund its stage 1 of development of a humanized anti-IgD antibody prototype to proceed to human clinical trials. IMT currently offers 10-20% of equity plus 2  seats on the Board of Directors (including CEO position) for US$16 million in capital funding and later stage options (negotiable).

Market and Technology Risk Mitigations

Therapeutic anti-IgD mAb leverages on compelling pre-clinical research evidence of therapeutic efficacy and mode of actions of anti-IgD mAb treatment in various clinically relevant animal models of human autoimmune diseases and skin allergic inflammation that have been published by peer-view and recently have been confirmed and corroborated by other independent studies.

Therapeutic anti-IgD mAb is designed as a first-in-class, disease-modifying immunomodulating therapeutic mAb that leverages on renowned success of modality of humanized mAb biologic as a blockbuster drug and clinically proven therapeutic targets of B cells and clinically validated mode of action of immune tolerance responses that have been clinically proven safe, effective and approved in multiple human diseases.

Anti-IgD mAb targets a very large global market of >US$200 billion in annual sales with a high demand and urgent unmet patient needs for a new treatment with a novel therapeutic approach that differentiates anti-IgD mAb from current therapeutic mAb to address their significant unmet patient. This represents a significant and attractive commercial opportunity for the clinical development of anti-IgD mAb.  

Using IMT’s research insights, know-hows, knowledges and IP technology, our therapeutic anti-IgD mAb will be designed with unique advantageous features in its mode of actions that distinguish anti-IgD mAb from the current mAb drugs in the market and enable anti-IgD mAb with potentially better safety profile and longer lasting efficacy to address the current unmet medical needs and gain a greater market share.

Risk Assessments & Mitigations

Our therapeutic anti-IgD mAb will be designed and developed with multiple indications targeting a range of chronic inflammatory conditions to achieve its market shares and sales revenue to justify its substantial cost of clinical development.

The nature of commercial development of therapeutic anti-IgD mAb by IMT is a high-risk high return investment venture but that are intrinsically to all therapeutic drug developments.  Industry reviews showed therapeutic mAb technology has a 22-25% probability of success in market approval (Kaplan & Reichert, mAb, 2019).  Based on our market and technology assessment, IMT has developed a business and technology risk mitigation strategy to minimize the risk on investment from a potential total loss due to technologically failure in human clinical trials.  Our therapeutic anti-IgD mAb leverages on unique technological advantageous features that will enable anti-IgD mAb to compete and gain market shares in a very large global market segment with significant unmet needs and demands.  To further minimize risks of investment, IMT will use its know-how, scientific insights and technological knowledge to strategically develop and design anti-IgD mAb as a platform that is adaptable to other modality platforms and enable it to be utilized for at least one therapeutic application in human.

Investing in the clinical development of therapeutic anti-IgD mAb will not only offer substantial financial returns but also support and advance our scientific research efforts to bring a potentially lifesaving treatment for a range of human diseases to the clinics to address the current significant unmet patient needs.

Investment in new drug development is a high risk and highly technical venture that require experienced professionals.  IMT recommends that investors seek independent scientific, investment and legal advice for all matters related to investment opportunities proposed by IMT.  For further information that may assist with due diligence and business assessment, please contact IMT.

Inquiries

Contact IMT for all inquiries regarding due diligence information, IMT technology assessment, collaborations, and investment opportunities.

Note: IMT business proposals may contain ‘forward-looking’ statements. IMT investment opportunity aims at professional and experienced investors with understanding of the risks involved in biotechnology investment. IMT recommends that investors seek independent advice for scientific and investment matters related to IMT technology and investment opportunities. For more details and inquiries to assist with due diligence assessments, please contact IMT.